Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?

15 Jul 2022

Abstract excerpt

Cell-free DNA (cfDNA) testing currently does not have a significant role in PDA management: it is insufficient to diagnose PDA, and its use is primarily restricted to identifying targetable mutations (if tissue is insufficient or unavailable). cfDNA testing has the potential to address critical needs in PDA management, such as pre-operative risk stratification (POR), prognostication, and predicting (and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35884515
DOI: 10.3390/cancers14143453

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?PMID 35884515Read ↗

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSemantic proximity Read ↗

Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic CancerSemantic proximity Read ↗

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic CancerSemantic proximity Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.Semantic proximity Read ↗

Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ DiscoverySemantic proximity Read ↗

Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencing.Semantic proximity Read ↗

Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

Circulating cell‐free <scp>DNA</scp> methylation‐based multi‐omics analysis allows early diagnosis of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Detection of mutated KRAS, TP53, CDK2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencingSemantic proximity Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.